A two-period microdosing study to determine the single-dose pharmacokinetics of ITMN-8187 after intravenous and oral administration in healthy subjects.
Completed
- Conditions
- Hepatitis Cvirus10047438
- Registration Number
- NL-OMON34901
- Lead Sponsor
- Intermune
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
- healthy male volunteers
- age between 18 and 65 years
- BMI is between 18.0 and 32.0 kg/m2
- non smoker or light or moderate smoker, i.e. * 5 cigarettes a day
- at screening the state of health must satisfy the entry requirements
Exclusion Criteria
Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Pharmacokinetics<br /><br>Safety</p><br>
- Secondary Outcome Measures
Name Time Method <p>n.a.</p><br>